187 related articles for article (PubMed ID: 24222664)
1. Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.
Neel NF; Stratford JK; Shinde V; Ecsedy JA; Martin TD; Der CJ; Yeh JJ
Mol Cancer Ther; 2014 Jan; 13(1):122-33. PubMed ID: 24222664
[TBL] [Abstract][Full Text] [Related]
2. Differential involvement of RalA and RalB in colorectal cancer.
Martin TD; Der CJ
Small GTPases; 2012; 3(2):126-30. PubMed ID: 22790202
[TBL] [Abstract][Full Text] [Related]
3. Polymer Nanovesicle-Mediated Delivery of MLN8237 Preferentially Inhibits Aurora Kinase A To Target RalA and Anchorage-Independent Growth in Breast Cancer Cells.
Inchanalkar S; Deshpande NU; Kasherwal V; Jayakannan M; Balasubramanian N
Mol Pharm; 2018 Aug; 15(8):3046-3059. PubMed ID: 29863884
[TBL] [Abstract][Full Text] [Related]
4. Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms.
Vigil D; Martin TD; Williams F; Yeh JJ; Campbell SL; Der CJ
J Biol Chem; 2010 Nov; 285(45):34729-40. PubMed ID: 20801877
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth.
Zhang Y; Ma Y; Wang Y; Mukhopadhyay D; Bi Y; Ji B
Pancreatology; 2022 Jun; 22(5):619-625. PubMed ID: 35550115
[TBL] [Abstract][Full Text] [Related]
6. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
8. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA.
Lim KH; Brady DC; Kashatus DF; Ancrile BB; Der CJ; Cox AD; Counter CM
Mol Cell Biol; 2010 Jan; 30(2):508-23. PubMed ID: 19901077
[TBL] [Abstract][Full Text] [Related]
9. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
11. Ral GTPase-activating protein regulates the malignancy of pancreatic ductal adenocarcinoma.
Yoshimachi S; Shirakawa R; Cao M; Trinh DA; Gao P; Sakata N; Miyazaki K; Goto K; Miura T; Ariake K; Maeda S; Masuda K; Ishida M; Ohtsuka H; Unno M; Horiuchi H
Cancer Sci; 2021 Aug; 112(8):3064-3073. PubMed ID: 34009715
[TBL] [Abstract][Full Text] [Related]
12. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
Zhao WG; Yu SN; Lu ZH; Ma YH; Gu YM; Chen J
Carcinogenesis; 2010 Oct; 31(10):1726-33. PubMed ID: 20675343
[TBL] [Abstract][Full Text] [Related]
13. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
14. RalA, a GTPase targeted by miR-181a, promotes transformation and progression by activating the Ras-related signaling pathway in chronic myelogenous leukemia.
Gu C; Feng M; Yin Z; Luo X; Yang J; Li Y; Li T; Wang R; Fei J
Oncotarget; 2016 Apr; 7(15):20561-73. PubMed ID: 26967392
[TBL] [Abstract][Full Text] [Related]
15. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
Wei F; Liu Y; Bellail AC; Olson JJ; Sun SY; Lu G; Ding L; Yuan C; Wang G; Hao C
Cancer Lett; 2012 Sep; 322(1):58-69. PubMed ID: 22342683
[TBL] [Abstract][Full Text] [Related]
16. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
18. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
19. RalA is overactivated in medulloblastoma.
Ginn KF; Fangman B; Terai K; Wise A; Ziazadeh D; Shah K; Gartrell R; Ricke B; Kimura K; Mathur S; Borrego-Diaz E; Farassati F
J Neurooncol; 2016 Oct; 130(1):99-110. PubMed ID: 27566179
[TBL] [Abstract][Full Text] [Related]
20. Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation.
Tecleab A; Zhang X; Sebti SM
J Biol Chem; 2014 Nov; 289(45):31296-309. PubMed ID: 25210032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
